Abstract Patients (pts) with fulminant progression (FPG) of multiple myeloma (MM) after autologous stem cell transplantation (ASCT) have poor prognosis. Pancytopenia, extramedullary disease, and/or renal impairment are often present, and treatment options are limited. We have retrospectively evaluated 31 pts with FPG of MM after ASCT who were treated upfront salvage therapy with melphalan 100 mg/m 2 (MEL 100) followed by PBSC support and consolidation therapy using regimens containing thalidomide (n=16) or bortezomib (n=15). The overall response rate (ORR) was 58% (18/31). After MEL 100, one patient achieved complete remission (3%), 26% of pts very good partial remission, 29% of pts partial remission, and 42% of pts stable disease. Progression within 3 months after MEL 100 occurred in 35% of pts. The median follow-up from MEL 100 was 8 months. The median TTP was 5 months (range, 2-15 months), and the median OS was 8 months (range, 3-23 months). There were no treatment-related deaths. In fulminant progression of MM, upfront MEL 100 is a safe salvage regimen with good response rate (ORR, 58%). Treatment with upfront MEL 100 followed by a thalidomide-or bortezomibbased regimen can prolong overall survival to more than 12 months in 33% of pts with fulminant progression of MM.
Introduction
The introduction of new drugs in the last decade has resulted in a significant progress in the treatment of multiple myeloma (MM) [1] . Combinations of novel agents with conventional therapies have prolonged progressionfree survival and increased response rates by overcoming drug resistance [2] [3] [4] .
Patients with rapid fulminant progression (FPG) of MM after autologous stem cell transplantation (ASCT) have poor prognosis. Treatment options are limited, and myeloma-related pancytopenia, extramedullary disease, and/or renal impairment are often present.
Encouraging results have been reported for the treatment with the combination of melphalan 100 mg/m 2 , bortezomib, thalidomide, and dexamethasone with stem cell support. The overall response rate (ORR) was as high as 65% in patients with refractory or relapsed myeloma [5] . Salvage treatment with upfront melphalan 100 mg/m 2 (MEL 100) followed by autologous peripheral blood stem cell (PBSC) support can stop the progression of MM almost immediately [6] . This strategy provides an opportunity for the application of consolidation treatment with novel drugs, such as thalidomide or bortezomib.
The aim of our retrospective analysis was to evaluate the efficacy and toxicity of upfront MEL 100 with PBSC support and subsequent consolidation with the combination of chemotherapy and novel drugs including thalidomide or bortezomib for FPG of MM after ASCT.
Patients and methods

Patients
From January 2004 to December 2006, progression of MM after ASCT was diagnosed in 102 patients (pts) at the Department of Internal Medicine-Hematooncology, Masaryk University Hospital, Brno. Thirty-one pts (30%) had fulminant progression of MM after ASCT and received treatment with melphalan 100 mg/m 2 followed by PBSC support at our department. The baseline characteristics of these pts are shown in Table 1 . The median age at MEL 100 initiation was 58 years. All 31 patients were informed about the benefits and risks associated with this treatment strategy and signed an informed consent.
Staging was carried out according to the Durie-Salmon staging system and the International Staging System [7, 8] . Standard criteria were used for the evaluation of disease response [9, 10] . Fulminant progression of MM was defined as a rapid progression occurring during 4-8 weeks with one of the following features: (1) high degree of bone marrow infiltration by plasma cells (> 50%) with peripheral pancytopenia (hemoglobin < 80 g/l and/or platelet count <50× 10 9 /l and/or neutrophil count <1.0×10 9 /l), (2) new presence of extramedullary disease, and (3) new renal impairment.
The median time from diagnosis of MM to the application of MEL 100 was 18 months (range, 8-50 months), and the median number of previous lines of therapy was one (range, 1-3). The median time from first ASCT to MEL 100 was 12 months (range, 2-44 months). Ten percent of pts (3/31) had an early fulminant relapse defined as FPG within 6 months of ASCT, and 48% of pts (15/31) had FPG within 12 months of their first ASCT. Cytogenetic analysis results were available for 26 of 31 pts (84%).
Treatment before fulminant relapse
All pts had been treated with four cycles of VAD (vincristine, doxorubicin, and dexamethasone). PBSCs were mobilized using high-dose cyclophosphamide 2.5 or 5 g/m 2 , with subsequent G-CSF at 5 or 10 μg/kg/day from day 3 to the last day of leukapheresis. PBSCs in a quantity sufficient for two ASCT procedures and a back-up were collected. The conditioning regimen consisted of melphalan 200 mg/m 2 . In addition, 35% of pts with >1st relapse (11/31) had been treated with the combination of chemotherapy and thalidomide or bortezomib as a part of relapse treatment before developing FPG and proceeding to the MEL 100 protocol.
Treatment for fulminant relapse
After the diagnosis of fulminant relapse, all pts were treated upfront with melphalan 100 mg/m 2 followed by PBSC support. After the recovery of peripheral blood counts, 52% of pts (16/ 
Statistical analysis
The Kaplan-Meier method was used to estimate time to progression (TTP) and overall survival (OS) probabilities. TTP was measured from the start of therapy with MEL 100 to disease progression, with deaths due to causes other than progression not counted as an event but censored at that time-point. OS was measured from the start of therapy with MEL 100 to death or most recent follow-up.
Results
Responses and survival
The ORR was 58% (18/31). After MEL 100, one patient achieved complete remission (3%, 1/31), 26% (8/31) of pts had very good partial response, and 29% (9/31) of pts partial remission. Furthermore, 42% (13/31) of patients had stable disease. No correlation between response duration and maximal response after MEL 100 was observed.
MM-related pancytopenia resolved after MEL 100 therapy with PBSC support in all affected pts (16/16). Improvement of renal impairment was observed in five of seven pts, including three pts who had complete normalization of renal functions. Complete regression of extramedullary disease was observed in four pts and a partial reduction of extramedullary MM in another three of ten pts. Early progression (i.e., progression within 3 months) after MEL 100 occurred in 35% (11/31) of pts.
The median follow-up from MEL 100 to the time of analysis was 8 months (range, 3-23 months). The median TTP was 5.0 months (range, 1-15 months; Fig. 1 ), and the median OS was 8.0 months (range, 3-23 months; Fig. 2 ). The subgroup with early relapse (3/31, FPG within 6 months after previous ASCT) had a very short median TTP and OS of 2 and 4 months, respectively. Differences in TTP and OS between groups with thalidomide consolidation and bortezomib consolidation were not statistically significant. Survival over 12 months after the initiation of MEL100 salvage therapy was observed in 33% of pts (10/31).
Cytogenetic analysis was performed in 84% of our pts (26/31). Abnormalities of chromosome 13 were found in 50% of pts (13/26), complex karyotype in 12% of pts (3/26), abnormalities of chromosome 1 in 14% of pts (4/ 26), translocation (4;14) in 12% of pts (3/26), and normal karyotype in 12% of pts (3/26). Thus, the majority of our cohort (23/26) had unfavorable cytogenetics as defined by Stewart et al. [11] . There was no treatment-related mortality to day+100 after MEL 100 infusion. The median time to neutrophil engraftment (neutrophil count >0.5×10 9 /l) was 11 days (range, 7-12 days). The median duration of hospital admission after MEL 100 was 21 days (range, 13-90 days). Grade 3 or 4 mucositis developed in 29% (9/31) of pts, and febrile neutropenia occurred in 39% (12/31) of pts.
Consolidation treatment
Consolidation treatment with novel anti-myeloma drugs was initiated in all pts (31/31). The median number of cycles of consolidation therapy was four (range, 1-6 cycles). Forty percent (12/31) of our pts discontinued the consolidation therapy because of MM progression and 6% (2/31) of pts due to adverse treatment-related events.
Adverse events were graded according to the National Cancer Institute Common Toxicity Criteria for Adverse Events, version 3 [12] . No grade 3 or 4 hematological toxicities were observed.
Thalidomide-based regimen Treatment-related neurological toxicities, such as tingling, numbness, and/or sedation, grade 1 or 2 were observed in 20% (3/15) of pts and grade 3 or 4 in 7% (1/15) of pts. Infectious toxicity included pneumonia in 2/15 (14%) pts, both of whom recovered after antimicrobial therapy. No other significant toxicities were observed.
Bortezomib-based regimen Grade 1/2 and grade 3 treatment-related neurological toxicities were observed at 19% (3/16) and 6% (1/16) of pts, respectively. Three pts had infectious complications (one patient pneumonia and two pts sinusitis) that required inpatient treatment; all infectious episodes resolved on parenteral broad-spectrum antibiotics.
Discussion
Fulminant progression of MM is usually rapidly fatal. It has been reported that MM with relapse or progression after ASCT who presented with only skeletal symptoms had a median survival of 30 months after relapse, while those with additional symptoms such as cytopenias or renal insufficiency had a significantly shorter median survival of approximately 18 months [13] . The median survival after initiation of salvage therapy was variable, ranging from 2 to 28 months depending on the type of relapse [13] .
Our cohort of 31 pts with FPG of MM had a very aggressive form of the disease and would be expected to succumb within several weeks if no active treatment were initiated. To check the fulminant progression of MM, we decided to use upfront treatment with intermediate-dose melphalan 100 mg/m 2 because of its well-established, powerful anti-myeloma effect. After this objective had been achieved, consolidation treatment with the combination of chemotherapy and bortezomib or thalidomide was started.
In refractory or relapsed myeloma, combinations including thalidomide or bortezomib with dexamethasone and cyclophosphamide have been extensively investigated [14] [15] [16] [17] [18] . The regimen containing cyclophosphamide, thalidomide, and dexamethasone was well tolerated and effective in patients with relapsed MM, achieving ORR of 83-90% [16, 17] . The combination of cyclophosphamide, bortezomib, and dexamethasone induced ORR in up to 75% of refractory or relapsed MM patients [15] . Thalidomide and bortezomib maintained their high efficacy and acceptable toxicity profile in patients with renal impairment [19, 20] .
Pancytopenia is often present in FPG of MM and presents an obstacle to treatment with combination regimens that include conventional cytostatics and novel drugs.
According to our findings, MEL 100 is a safe salvage regimen with good response rate (58% ORR) and acceptable toxicity in FPG of MM. Despite the fact that the outcome of FPG of MM remains poor, a substantial part of pts benefits from MEL 100 treatment and subsequent combination thalidomide-or bortezomib-based regimens. In our hands, this treatment strategy resulted in a survival of over 12 months in 33% of pts who developed this highly unfavorable form of multiple myeloma.
